Blog - Page 5 of 5373 - QualityStocks

FridayJun 06, 2025 12:45 pm

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Out in Booming Gold Market, Offers Strategic Investment Avenue

The gold market's current dynamics underscore the metal's enduring appeal Lahontan Gold boasts a portfolio of four gold and silver projects located in Nevada's prolific Walker Lane LGCXF’s management team comprises seasoned professionals with extensive experience in mineral exploration, project development and corporate finance LGCXF recently named as “one of the best gold developers in Nevada” In an era marked by economic volatility and geopolitical tensions, gold has reasserted itself as a premier safe-haven asset. Gold prices have soared to unprecedented levels, surpassing $3,400 per ounce, driven by factors such as trade disputes, inflationary pressures and global uncertainty (https://ibn.fm/1Z7sV). This bullish…

FridayJun 06, 2025 12:00 pm

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances

The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates. Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings. INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity. The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety. INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery. Intelligent Bio Solutions (NASDAQ: INBS),…

FridayJun 06, 2025 11:15 am

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Tests Potential for Streamlining Tailings Process, Offering Important Cost and Environment Benefits

ESGold is a gold and silver company preparing for production later this year at a tailings reclamation site in Quebec abandoned by the previous operator The gold and silver resource developer expects to concentrate on reprocessing the tailings for the near-term to extract mica and any remaining gold and silver, anticipating that the resulting mica concentrate will be useful in a wide variety of building and roadwork materials ESGold plans to build revenue through the reuse project, which can then help fund planned exploration at its Quebec property covering 13,116 hectares (about 32,410 acres) The company is currently conducting testing…

FridayJun 06, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL

Soligenix’s HyBryte(TM) is a photodynamic therapy using synthetically manufactured hypericin, one of the most photoactive compounds available. The therapeutic potential of HyBryte(TM) has been demonstrated through multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients. HyBryte(TM) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency. Cutaneous T-cell lymphoma (“CTCL”) is a rare and debilitating form of non-Hodgkin’s lymphoma that primarily affects the skin, posing both physical and emotional challenges for those diagnosed. With limited treatment options available and no definitive cure, the need for innovative, safe and effective…

FridayJun 06, 2025 9:35 am

QualityStocksNewsBreaks – Authentic Holdings (OTC: AHRO) Subsidiary Maybacks Signs Streaming Deal With Plex

Authentic Holdings (OTC: AHRO) announced that its wholly owned subsidiary, Maybacks Global Entertainment, LLC, has entered into a licensing and distribution agreement with Plex GmbH to bring its iDreamCTV network brands—Toro TV, Comfy TV, Winnie’s World, and iCowboy—to a global streaming audience. The partnership leverages Plex’s AVOD and FAST channel infrastructure to monetize and distribute Maybacks’ content across its 25 million-user platform. Following its acquisition of Goliath Motion Picture Promotions, Maybacks is pivoting from traditional film sales to building proprietary media brands with scalable digital reach. To view the full press release, visit https://ibn.fm/hnCSv About Authentic Holdings Authentic Holdings combines…

ThursdayJun 05, 2025 1:38 pm

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads. The company unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The announcement reads, “Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical models. Calidi has further advanced this technology with CLD-401, its first…

ThursdayJun 05, 2025 11:15 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics. HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer. NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical…

ThursdayJun 05, 2025 10:30 am

Nightfood Holdings Inc. (NGTF) Taps Proven Leaders to Accelerate Hospitality Innovation

Nightfood Holdings new executives have strong track records in a variety of spaces NGTF's new leadership team is poised to leverage their combined expertise to facilitate the company's growth and innovation The foundation of any successful company often rests on the quality and vision of its leadership. Experienced executives can be the deciding factor between stagnation and rapid growth, particularly in dynamic sectors such as consumer goods and hospitality. That’s why Nightfood Holdings (OTCQB: NGTF) made waves recently with its announcement of new senior leadership appointments aimed at accelerating innovation and expansion across its growing portfolio of hospitality-focused services. According…

ThursdayJun 05, 2025 10:00 am

QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, PC111—a monoclonal antibody targeting the Fas/FasL pathway—holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders. The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer. To view the full press release, visit https://ibn.fm/qoRQ1…

ThursdayJun 05, 2025 9:50 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled "The Future and Promise of TPI 287," will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier. To view…

Site Search

Company Search